ALDH2 rs671基因多态性与非酒精性脂肪性肝病相关性研究*

doi:10.3969/j.issn.1672-5069.2019.06.018

实用肝脏病杂志 ›› 2019, Vol. 22 ›› Issue (6): 848-851.doi: 10.3969/j.issn.1672-5069.2019.06.018

ALDH2 rs671基因多态性与非酒精性脂肪性肝病相关性研究^*

李颖怡, 郭翠芬, 章瑞南, 汪保灿, 潘勤, 汪余勤, 曹海霞, 范建高

362000 福建省泉州市第一医院消化内科（李颖怡）; 云南省保山市龙陵县人民医院（郭翠芬）; 上海交通大学医学院附属新华医院消化科（章瑞南,汪保灿,潘勤,汪余勤,曹海霞,范建高）

收稿日期:2019-02-26 出版日期:2019-11-13 发布日期:2019-11-13
通讯作者: 曹海霞,E-mail：caohaixia204106@126.com
作者简介:李颖怡,医学硕士。主要从事慢性肝病防治研究。E-mail：liyingyi0924@126.com
基金资助:
*国家自然科学基金青年基金项目（编号：81600464）

Correlation of polymorphism of ALDH2 rs671 to morbidity in individuals prone to nonalcoholic fatty liver disease

Li Yingyi, Guo Cuifen, Zhang Ruinan, et al.

Department of Gastroenterology,Xinhua Hospital,JiaoTong University School of Medicine,Shanghai 200092,China Correspongding author:Cao Haixia, E-mail:caohaixia204106@126.com

Received:2019-02-26 Online:2019-11-13 Published:2019-11-13

摘要/Abstract

摘要： 目的研究乙醛脱氢酶2（ALDH2）基因rs671多态性与非酒精性脂肪性肝病（NAFLD）发病的相关性。方法在120例研究对象,行肝脏硬度和受控衰减参数（CAP）及血ALDH2 rs671多态性检测,采用非条件Logistic回归控制混杂因素,计算比值比（OR）及其95%可信区间（CI）,判断基因多态性与NAFLD患病的相对风险度。结果根据CAP检测结果发现脂肪肝73例,无脂肪肝人群47例;脂肪肝组和无脂肪肝组ALDH2 rs671基因GA/AA型比例分别为52.1%和34.0%（P<0.05）;女性和超重人群中脂肪肝组GA/AA型比例分别为48.8%和53.3%,显著高于无脂肪肝组的22.2%和23.1%（P<0.05）;GA/AA型者脂肪肝患病风险升高3.756倍,其体质量、臀围、腰高比超标比例显著高于GG型者（P<0.05）,血清GGT水平为（55.57±99.97） U/L,显著高于GG型者[（38.17±48.02）U/L,P<0.05]。结论 ALDH2 rs671突变可增加NAFLD的患病风险,其发病机制和防治措施还需要进一步研究。

关键词: 非酒精性脂肪性肝病, 乙醛脱氢酶2, 单核苷酸多态性, 患病风险

Abstract: Objective The purpose of this study was to investigate the correlation of polymorphism of acetaldehyde dehydrogenase 2 （ALDH2） rs671 to morbidity in individuals prone to nonalcoholic fatty liver disease （NAFLD）. Methods Transient elastography and sequencing of ALDH2 rs671 were performed in 120 subjects. The odd ratio and confidence interval were calculated by Logistic analysis. Results Out of the 120 individuals,73 had NAFLD and 47 had not by the controlled attenuation parameter;the proportions of ALDH2 genotype GA/AA were 52.1% in the fatty liver group,and 34.0% in the non-fatty liver group（P<0.05）;out of female and overweight,the proportions of GA/AA type（48.8% vs. 53.3%）in the fatty liver group were both significantly higher than in non-fatty liver group （22.2% vs.23.1%,P<0.05）;Logistic analysis revealed that carriers of GA/AA type was at 3.756 -fold higher risk of NAFLD compared with non-carriers;the carriers of GA/AA type had significantly higher body weight,hip circumference and waist height ratio（P<0.05）,and serum GGT level in carriers of GA/AA type was（55.57±99.97） U/L,significantly higher than that in carriers of GG type【（38.17±48.02） U/L,P<0.05】. Conclusion The mutation of ALDH2 rs671 might increase the risk of having NAFLD,which needs further investigation.

Key words: Nonalcoholic fatty liver disease, Acetaldehyde dehydrogenase 2, Single nucleotide polymorphism, Disease hazard

李颖怡, 郭翠芬, 章瑞南, 汪保灿, 潘勤, 汪余勤, 曹海霞, 范建高. ALDH2 rs671基因多态性与非酒精性脂肪性肝病相关性研究^*[J]. 实用肝脏病杂志, 2019, 22(6): 848-851.

Li Yingyi, Guo Cuifen, Zhang Ruinan, et al.. Correlation of polymorphism of ALDH2 rs671 to morbidity in individuals prone to nonalcoholic fatty liver disease[J]. Journal of Practical Hepatology, 2019, 22(6): 848-851.

参考文献

[1] Fan JG,Kim SU,Wong VW.New trends on obesity and NAFLD in Asia. J Hepatol,2017,67(4):862-873.
[2] Perumpail BJ,Khan MA,Yoo ER,et al.Clinical epidemiology and disease burden of nonalcoholic fatty liver disease. World J Gastroenterol,2017,23(47):8263-8276.
[3] 马振增,陆伦根. 非酒精性脂肪性肝病与肝硬化. 实用肝脏病杂志,2016(2):135-138.
[4] de Medeiros IC,de Lima JG. Is nonalcoholic fatty liver disease an endogenous alcoholic fatty liver disease-A mechanistic hypothesis. Med Hypoth,2015,85(2):148-152.
[5] Eslam M,Valenti L,Romeo S.Genetics and epigenetics of NAFLD and NASH:Clinical impact. J Hepatol,2018,68(2):268-279.
[6] Del C J,Gallego-Duran R,Gallego P,et al.Genetic and epigenetic regulation in nonalcoholic fatty liver disease (NAFLD). Int J Mol Sci,2018,19(3):334-338.
[7] Chen CH,Ferreira JC,Gross ER,et al.Targeting aldehyde dehydrogenase 2:new therapeutic opportunities. Physiol Rev,2014,94(1):1-34.
[8] Zhu Y,Zhang D,Zhou D,et al.Susceptibility loci for metabolic syndrome and metabolic components identified in Han Chinese:a multi-stage genome-wide association study. J Cell Mol Med,2017,21(6):1106-1116.
[9] Younossi Z,Anstee QM,Marietti M,et al.Global burden of NAFLD and NASH:trends,predictions,risk factors and prevention. Nat Rev Gastroenterol Hepatol,2018,15(1):11-20.
[10] de Ledinghen V,Vergniol J,Capdepont M,et al. Controlled attenuation parameter(CAP) for the diagnosis of steatosis:a prospective study of 5323 examinations. J Hepatol,2014,60(5): 1026-1031.
[11] de Ledinghen V,Wong GL,Vergniol J,et al. Controlled attenuation parameter for the diagnosis of steatosis in non-alcoholic fatty liver disease. J Gastroenterol Hepatol,2016,31(4):848-855.
[12] Shen F,Zheng R D,Mi YQ,et al.Controlled attenuation parameter for non-invasive assessment of hepatic steatosis in Chinese patients. World J Gastroenterol,2014,20(16):4702-4711.
[13] 李岩,郝志华,陈春彦,等. 瞬时弹性成像对非酒精性脂肪性肝病的应用价值. 中国超声医学杂志,2014,20(5):414-418.
[14] 李颖怡,曹海霞,汪余勤. 乙醛脱氢酶2与非酒精性脂肪性肝病相关性的研究进展. 国际消化病杂志,2018,32(1):10-15.
[15] Yoshida A,Huang I Y,Ikawa M.Molecular abnormality of an inactive aldehyde dehydrogenase variant commonly found in Orientals. Proc Natl Acad Sci U S A,1984,81(1):258-261.
[16] Lai C L,Yao C T,Chau G Y,et al.Dominance of the inactive Asian variant over activity and protein contents of mitochondrial aldehyde dehydrogenase 2 in human liver. Alcohol Clin Exp Res,2014,38(1):44-50.
[17] Li H,Toth E,Cherrington NJ.Alcohol metabolism in the progression of human nonalcoholic steatohepatitis. Toxicol Sci,2018,164(2):428-438.
[18] Stachowicz A,Olszanecki R,Suski M,et al.Mitochondrial aldehyde dehydrogenase activation by Alda-1 inhibits atherosclerosis and attenuates hepatic steatosis in apolipoprotein E-knockout mice. J Am Heart Assoc,2014,3(6):e1329.
[19] You M,Fischer M,Deeg MA,et al.Ethanol induces fatty acid synthesis pathways by activation of sterol regulatory element-binding protein (SREBP). J Biol Chem,2002,277(32):29342-29347.
[20] Oniki K,Morita K,Watanabe T,et al.The longitudinal effect of the aldehyde dehydrogenase 2*2 allele on the risk for nonalcoholic fatty liver disease. Nutr Diabetes,2016,6:e210.

ALDH2 rs671基因多态性与非酒精性脂肪性肝病相关性研究^*

Correlation of polymorphism of ALDH2 rs671 to morbidity in individuals prone to nonalcoholic fatty liver disease

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	任俞霏, 陈小青, 孔维宗, 王迎春. 丹酚酸B对非酒精性脂肪性肝病细胞模型自噬功能的影响^*[J]. 实用肝脏病杂志, 2019, 22(6): 804-807.
[2]	邢欣, 魏重操, 周咪咪, 李小玲, 邓江, 鲁晓岚. 牛磺熊去氧胆酸与熊去氧胆酸治疗非酒精性脂肪性肝病患者疗效和安全性的Meta分析[J]. 实用肝脏病杂志, 2019, 22(6): 852-855.
[3]	张胥磊, 杨庆余, 韩秋玉, 缪鋆鋆, 蔡仁诚, 马亦旻. 自拟中药治疗非酒精性脂肪性肝病患者血清炎症反应指标水平的变化*[J]. 实用肝脏病杂志, 2019, 22(5): 660-663.
[4]	张兰华, 邵琴, 夏振娟. 非酒精性脂肪性肝病儿童血清25-（OH）D3和IL-17水平变化初步研究^*[J]. 实用肝脏病杂志, 2019, 22(4): 522-525.
[5]	谢晓, 刘婷, 董志霞, 夏幼辰, 张启迪, 曲颖, 蔡晓波, 徐铭益, 陆伦根. FibroTouch检测肝脏受控衰减参数对肝脂肪变的诊断价值分析^*[J]. 实用肝脏病杂志, 2019, 22(4): 526-529.
[6]	符亮, 吴冬冰, 纪新尊, 万鸿兴, 李文刚, 饶卉明, 钟静, 江婷婷. 超声定量评估非酒精性脂肪性肝病患者肝脏ARFI值对显著NASH的诊断价值分析[J]. 实用肝脏病杂志, 2019, 22(3): 377-380.
[7]	朱光曦（综述）, 文良志, 陈东风（审校）. 非酒精性脂肪性肝病相关肝细胞癌发病机制研究进展[J]. 实用肝脏病杂志, 2019, 22(3): 453-456.
[8]	霍会芹,巩晓红,李正宏. 采用实时三维超声和斑点追踪技术评价非酒精性脂肪性肝病肝硬化患者右心功能^*[J]. 实用肝脏病杂志, 2019, 22(2): 244-247.
[9]	苏淑婷,钟燕（综述）,宓余强（审校）. 非酒精性脂肪性肝病分级分期管理研究进展[J]. 实用肝脏病杂志, 2019, 22(2): 293-296.
[10]	谢晓（综述）,陆伦根（审校）. 无创诊断和评估非酒精性脂肪性肝炎研究进展^*[J]. 实用肝脏病杂志, 2019, 22(2): 301-306.
[11]	张枫, 阎妍. 非酒精性脂肪性肝病患者血清载脂蛋白B水平及其临床意义探讨^*[J]. 实用肝脏病杂志, 2019, 22(1): 61-64.
[12]	宋娜, 刘晓燕, 刘畅, 山秀杰, 苏东峰, 李丽慧. 非酒精性脂肪性肝病合并2型糖尿病患者血浆促甲状腺激素水平变化及其临床意义^*[J]. 实用肝脏病杂志, 2019, 22(1): 65-68.
[13]	崔清华, 陶红, 王晓玥, 张凤丽. 非酒精性脂肪性肝病患者血清糖化血红蛋白水平和心功能指标的变化研究^*[J]. 实用肝脏病杂志, 2019, 22(1): 69-72.
[14]	钟燕, 苏淑婷综述, 宓余强审校. 非酒精性脂肪性肝病治疗研究进展[J]. 实用肝脏病杂志, 2019, 22(1): 145-148.
[15]	胡虎兰综述, 朱梦飞, 施军平审校. 慢性乙型肝炎合并非酒精性脂肪性肝病临床研究进展^*[J]. 实用肝脏病杂志, 2019, 22(1): 149-152.